Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced the appointment of Dr. Angus Grant, Ph.D., as EVP,
Business Development. Dr. Grant will begin his employment on August
1, 2023, and will be based out of Teva's US headquarters in
Parsippany, NJ.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230727524382/en/
(Photo: Business Wire)
Dr. Grant joins Teva with over 25 years of experience in the
global pharmaceutical and biotech industry, with an exceptional
track record across a variety of fields including Business
Development, R&D and Regulatory Affairs. Most recently, Dr.
Grant served as the Chief Business Executive at BeiGene, overseeing
business development, clinical and business insights and valuation,
investments and collaborations, and alliance management. Before his
tenure at BeiGene, Dr. Grant served as CEO of the Dementia
Discovery Fund (DDF), a specialist venture capital fund focused on
therapeutics for age-related dementias and neurodegenerative
disease. Earlier in his career, Dr. Grant spent 12 years at
Celgene, serving in various leadership roles including Corporate
Vice President of Business Development, and Vice President,
Regulatory Affairs.
Richard Francis, Teva’s President and CEO said: “We are pleased
to welcome a leader of Angus caliber to our executive team at Teva.
With a distinguished career spanning over more than two and a half
decades in the global pharmaceutical and biotech industry, his
breadth of experience and demonstrated expertise in business
development, innovative R&D, and scientific affairs will be a
significant asset to our organization.
Mr. Francis continued: “These are exciting times at Teva, as we
embark on our Pivot to Growth strategy, a crucial element of which
involves amplifying our innovation through our already promising
pipeline as well as fortifying our business development endeavors.
I have full confidence in Angus leadership and firmly believe that
he is exceptionally positioned to lead the business development
efforts during this era of transformation. His contributions will
be instrumental in driving external innovation, fostering
collaborations across academia, biotech, and pharmaceutical
sectors, and enhancing Teva's momentum in bringing innovative
therapies to patients worldwide."
Dr. Grant stated, "I am thrilled to be joining Teva's executive
leadership team and am inspired by Teva's purpose and strategy to
drive growth by stepping up and leaning more into innovation. I am
looking forward to work with the extended Teva team and leading the
excellent business development team, to drive innovation and to
partner with the best minds in academia and the industry to bring
meaningful impact and value for patients worldwide and for
Teva."
Angus Grant bio
Angus has held executive leadership positions at BeiGene, a
global, commercial-stage biotechnology company, where he led
Strategy and Partnering. Angus also served as CEO of the Dementia
Discovery Fund (DDF), a specialist venture capital fund focused on
therapeutics for age-related dementias and neurodegenerative
disease and in senior leadership positions at Celgene. Earlier in
his career, Dr. Grant worked in business development and regulatory
roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline
Beecham. After completing his PhD in Anatomy/ Immunology, Angus
joined a clinical laboratory within the NIH prior to joining the
FDA where he focused on cell and gene therapy IND processing.
In 2006, Angus joined Celgene and held various leadership over
his 12 years, including Corporate VP Business Development. Angus
led deals ranging from R&D and commercialization collaborations
to early equity investments, supply collaborations, M&A such as
$9B Juno acquisition in 2018, and licensing both globally and
regionally.
Angus departed Celgene to serve as CEO of Dementia Discovery
Fund (DDF), inspired by their mission to invest in and build the
early-stage biotech companies most likely to develop transformative
treatments for neurodegenerative diseases, to the benefit of the
millions of people suffering from this health crisis of the 21st
century that has longed lacked effective treatments.
Dr. Grant received his undergraduate degree from the University
of Richmond and a Ph.D. in anatomy and immunology from the Medical
College of Virginia, and he completed his postdoctoral training at
the National Cancer Institute. Dr. Grant currently serves as the
Chairman of the Board for Toronto Innovation and Acceleration
Partners. He is a published scientist, co-authoring more than 15
articles in peer-reviewed scientific journals.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative medicines research and
operations supporting our growing portfolio of innovative medicines
and biopharmaceutical products.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to our business and operations
in general, including our ability to attract, hire and retain
highly skilled key personnel, our ability to successfully compete
in the marketplace, including our ability to develop and
commercialize biopharmaceutical products, competition for our
specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our
ability to execute on our Pivot to Growth strategy; our ability to
achieve expected results from investments in our product pipeline,
our ability to develop and commercialize additional pharmaceutical
products, and the effectiveness of our patents and other measures
to protect our intellectual property rights; our substantial
indebtedness; regulatory and litigation matters, including failure
to comply with complex legal and regulatory environments; other
financial and economic risks; and other factors discussed in our
Quarterly Report on Form 10-Q for the first quarter of 2023 and in
our Annual Report on Form 10-K for the year ended December 31,
2022, including in the section captioned “Risk Factors.”
Forward-looking statements speak only as of the date on which they
are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained herein,
whether as a result of new information, future events or otherwise.
You are cautioned not to put undue reliance on these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727524382/en/
IR Contacts United States Ran Meir (267) 468-4475
Israel Yael Ashman 972 (3) 914-8262 PR Contacts
United States Kelley Dougherty (973) 658-0237 Israel
Eden Klein 972 (3) 906-2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024